These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31404946)

  • 1. Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.
    Sullivan RD; Mehta RM; Tripathi R; Gladysheva IP; Reed GL
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31404946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Low-Sodium Diet Boosts Ang (1-7) Production and NO-cGMP Bioavailability to Reduce Edema and Enhance Survival in Experimental Heart Failure.
    Tripathi R; Sullivan RD; Fan TM; Mehta RM; Gladysheva IP; Reed GL
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac-Specific Overexpression of Catalytically Inactive Corin Reduces Edema, Contractile Dysfunction, and Death in Mice with Dilated Cardiomyopathy.
    Tripathi R; Sullivan RD; Fan TM; Houng AK; Mehta RM; Reed GL; Gladysheva IP
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
    Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
    Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ; Cangiano JL; Altieri PI; Escobales N
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin Activity in Heart Failure with Reduced Systolic Function-New Insights.
    Sullivan RD; Mehta RM; Tripathi R; Reed GL; Gladysheva IP
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy.
    Tripathi R; Sullivan R; Fan TM; Wang D; Sun Y; Reed GL; Gladysheva IP
    PLoS One; 2017; 12(12):e0189315. PubMed ID: 29240788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).
    Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL
    Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depressed Corin Levels Indicate Early Systolic Dysfunction Before Increases of Atrial Natriuretic Peptide/B-Type Natriuretic Peptide and Heart Failure Development.
    Tripathi R; Wang D; Sullivan R; Fan TH; Gladysheva IP; Reed GL
    Hypertension; 2016 Feb; 67(2):362-7. PubMed ID: 26667411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
    van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
    J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
    Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
    JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.
    Sidik NP; Solomon SD; Latini R; Maggioni AP; Wright M; Gimpelewicz CR; Pitt B; McMurray JJ
    Cardiovasc Drugs Ther; 2011 Aug; 25(4):315-21. PubMed ID: 21779784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.
    Seed A; Gardner R; McMurray J; Hillier C; Murdoch D; MacFadyen R; Bobillier A; Mann J; McDonagh T
    Eur J Heart Fail; 2007 Nov; 9(11):1120-7. PubMed ID: 17945530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
    Pitt B; Latini R; Maggioni AP; Solomon SD; Smith BA; Wright M; Prescott MF; McMurray JJ
    Eur J Heart Fail; 2011 Jul; 13(7):755-64. PubMed ID: 21467028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.
    Vaduganathan M; Cheema B; Cleveland E; Sankar K; Subacius H; Fonarow GC; Solomon SD; Lewis EF; Greene SJ; Maggioni AP; Böhm M; Zannad F; Butler J; Gheorghiade M
    Eur J Heart Fail; 2018 Apr; 20(4):677-686. PubMed ID: 29143416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).
    Gheorghiade M; Albaghdadi M; Zannad F; Fonarow GC; Böhm M; Gimpelewicz C; Botha J; Moores S; Lewis EF; Rattunde H; Maggioni A;
    Eur J Heart Fail; 2011 Jan; 13(1):100-6. PubMed ID: 21123186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.